You are here

Microneedle Delivery of Zanamivir for Treatment of Influenza Infections

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43AI129122-01A1
Agency Tracking Number: R43AI129122
Amount: $572,526.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NIAID
Solicitation Number: PA16-302
Solicitation Year: 2016
Award Year: 2017
Award Start Date (Proposal Award Date): 2017-03-01
Award End Date (Contract End Date): 2019-03-31
Small Business Information
Ann Arbor, MI 48108-7906
United States
DUNS: 156551699
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (734) 223-6862
Business Contact
Phone: (734) 663-4233
Research Institution

Yearly influenza epidemics strike millions of peoplecausing up todeathsFatality caused by most
seasonal influenza viruses is ltbut with significant mortality in the young and the elderly populationsWhen a new pathogenic influenza strain enters the populationa pandemic could kill tens of millions of people
with a negative economic impact estimated to be overbillion dollarsInfluenza virus is a NIAID category C
priority biothreatcharacterized as an emerging agent that is readily available and disseminatedDue to the
incomplete efficacy of the current vaccineseffective drug treatment is necessaryPresentlyinfluenza treatment
is only somewhat effectiveand some influenza strains are resistant to the currently marketed therapeuticsadamantanes and the neuraminidase inhibitor TamifluHoweverzanamivirRelenzaremains highly active
against oseltamivir resistant influenza strainsbut its therapeutic impact is severely limited by its route of
administrationvia oral inhalationwhich renders it unsuitable for patients with a compromised respiratory
systemThereforedevelopment of a novel delivery alternative for zanamivir as we propose hereis poised to
address a significant unmet medical needApplication of a transdermal microneedle delivery strategy to the anti viraland particularly anti influenzamarket
offers a number of solutions to large unmet medical needsand represents an attractive market entry strategyTransdermal delivery systems offer a number of improvements over other delivery systemsPatches do not
require swallowingeliminating oral side effectsPermeation through the skin allows the drug to directly enter
the systemic circulation and avoid any absorption and first pass barriers a drug might encounter with oral
deliveryFinallytransdermal delivery avoids skin puncture by syringe needleseliminating pain and patient visits
to a physicianTransdermal delivery of ZAN is desirable during an influenza outbreakas large numbers of
patients can be reachedThe Phase I portion of this proposal will involve formulation optimization of the prototype patch and subsequent
pharmacokinetic and efficacy testing in miceThe final study for this proposal will be a dermatotoxicology studies
to assess skin irritation of the final patches in rabbitsThe end result of this work will be a noveltransdermal delivery approach for zanamivir with demonstrated
efficacyPK and initial preclinical safety data ready to complete preclinical development activities leading to the
opening of an INDWe have assembled a team of expert advisors and collaborators to ensure successful
completion of this research plan

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government